Jing Zhang

Jing Zhang

Auto-generated profile, based on publicly available information

Jing Zhang

Institute for Translational Medicine on Cell Fate and Disease Shanghai Ninth People's Hospital Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education Department of Pathophysiology Shanghai Jiao Tong University School of Medicine Shanghai 200025 China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
YWYan Wu
Yan Wu
HJHuike Jiao
Huike Jiao
YYYangbo Yue
Yangbo Yue
KHKang He
Kang He
YJYuting Jin
Yuting Jin
QING ZHONGQING ZHONG
QING ZHONG

11 January 2024 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
ZZZili Zhang
Zili Zhang
HZHong Zhou
Hong Zhou
WGWenjia Gu
Wenjia Gu
YWYuehan Wei
Yuehan Wei
SMShan Mou
Shan Mou
QING ZHONGQING ZHONG
QING ZHONG

20 October 2011 in Genes & Development
Verified
Journal Article
Open access
PDF file
JZJing Zhang
Jing Zhang
SKShu Kan
Shu Kan
BHBrian Huang
Brian Huang
ZHZhenyue Hao
Zhenyue Hao
TMTak W. Mak
Tak W. Mak
QING ZHONGQING ZHONG
QING ZHONG
Histone deacetylases (HDACs) are major epigenetic modulators involved in a broad spectrum of human diseases including cancers. Administration of HDAC inhibitors (HDACis) leads to growth inhibition, differentiation, and apoptosis of cancer cells. Understanding the regulatory mechanism of HDACs is imperative to harness the therapeutic potentials of HDACis. Here we show that HDACi- and DNA damage-induced apoptosis are severely compromised in mouse embryonic fibroblasts lacking a HECT domain ubiquitin ligase, Mule (Mcl-1 ubiquitin ligase E3). Mule specifically targets HDAC2 for ubiquitination and degradation. Accumulation of HDAC2 in Mule-deficient cells leads to compromised p53 acetylation as well as crippled p53 transcriptional activation, accumulation, and apoptotic response upon DNA damage and Nutlin-3 treatments. These defects in Mule-null cells can be partially reversed by HDACis and fully rescued by lowering the elevated HDAC2 in Mule-null cells to the normal levels as in wild-type cells. Taken together, our results reveal a critical regulatory mechanism of HDAC2 by Mule and suggest this pathway determines the cellular response to HDACis and DNA damage.

16 July 2007 in Oncogene
Verified
Journal Article
Closed access
LSL-P Song
L-P Song
JZJ Zhang
J Zhang
SWS-F Wu
S-F Wu
YHY Huang
Y Huang
QZQ Zhao
Q Zhao
Guoqiang ChenGuoqiang Chen
Guoqiang Chen

24 September 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JZJing Zhang
Jing Zhang
YWYuehan Wei
Yuehan Wei
YYYangbo Yue
Yangbo Yue
HJHuike Jiao
Huike Jiao
YWYan Wu
Yan Wu
QING ZHONGQING ZHONG
QING ZHONG
One of the most critical axes for cell fate determination is how cells respond to excessive reactive oxygen species (ROS)—oxidative stress. Extensive lipid peroxidation commits cells to death via a distinct cell death paradigm termed ferroptosis. However, the molecular mechanism regulating cellular fates to distinct ROS remains incompletely understood. Through siRNA against human receptor-interacting protein kinase (RIPK) family members, we found that RIPK4 is crucial for oxidative stress and ferroptotic death. Upon ROS induction, RIPK4 is rapidly activated, and the kinase activity of RIPK4 is indispensable to induce cell death. Specific ablation of RIPK4 in kidney proximal tubules protects mice from acute kidney injury induced by cisplatin and renal ischemia/reperfusion. RNA sequencing revealed the dramatically decreased expression of acyl-CoA synthetase medium-chain (ACSM) family members induced by cisplatin treatment which is compromised in RIPK4-deficient mice. Among these ACSM family members, suppression of ACSM1 strongly augments oxidative stress and ferroptotic cell death with induced expression of ACS long-chain family member 4, an important component for ferroptosis execution. Our lipidome analysis revealed that overexpression of ACSM1 leads to the accumulation of monounsaturated fatty acids, attenuation of polyunsaturated fatty acid (PUFAs) production, and thereby cellular resistance to ferroptosis. Hence, knockdown of ACSM1 resensitizes RIPK4 KO cells to oxidative stress and ferroptotic death. In conclusion, RIPK4 is a key player involved in oxidative stress and ferroptotic death, which is potentially important for a broad spectrum of human pathologies. The link between the RIPK4–ASCM1 axis to PUFAs and ferroptosis reveals a unique mechanism to oxidative stress–induced necrosis and ferroptosis.

5 April 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JZJing Zhang
Jing Zhang
CTChristina Trojel-Hansen
Christina Trojel-Hansen
JWJianghuang Wang
Jianghuang Wang
ZZZili Zhang
Zili Zhang
XWXing Wang
Xing Wang
QING ZHONGQING ZHONG
QING ZHONG
Many anticancer agents induce apoptosis, mitotic catastrophe or cellular senescence. Here, we report the functional characterization of an experimental inducer of tumor necrosis factor (TNF)-independent necrosis, necrocide-1 (NC1). NC1 (but not its stereoisomer) killed a panel of human cancer cells (but not normal cells) at nanomolar concentrations and with a non-apoptotic, necrotic morphotype, both in vitro and in vivo. NC1-induced killing was not inhibited by caspase blockers, anti-apoptotic BCL2 overexpression or TNFα neutralization, suggesting that NC1 elicits a bona fide necrotic pathway. However, pharmacological or genetic inhibition of necroptosis, pyroptosis and ferroptosis failed to block NC1-mediated cell death. Instead, NC1 elicited reactive oxygen species (ROS) production by mitochondria, and elimination of mitochondrial DNA, quenching of mitochondrial ROS, as well as blockade of mitochondrial permeability transition with cyclosporine A, interfered with NC1-induced cell death. NC1 induced hallmarks of immunogenic cell death incurring calreticulin (CALR) exposure, ATP secretion and high mobility group box 1 (HMGB1) release. Taken together, these data identify a previously uncharacterized signaling cascade leading to an immunogenic variant of mitochondrion-regulated necrosis, supporting the notion that eliciting regulated necrosis may constitute a valid approach for anticancer therapy.